NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

It’s hard to believe they did a terrible job with the application when they took over 3 years to submit and hired some of the best consultants to pretty much do the job for them.

The likely reason is that the data is messy and NWBO is unable to address all of MHRA’s concern. However, MHRA continues to give NWBO extra leeway given the political and clinical community pressure. At some point in 2026, the MHRA may be left with no choice but to send a rejection letter.